Cargando…

MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab

Trastuzumab is the standard treatment for HER2+ breast cancer (BC) patients, and even though it significantly improved their clinical outcome, 50% of them do not benefit from this drug and disease recurs, underlining the need of reliable predictive biomarkers and new therapeutic strategies. Striking...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cataldo, Alessandra, Piovan, Claudia, Plantamura, Ilaria, D’Ippolito, Elvira, Camelliti, Simone, Casalini, Patrizia, Giussani, Marta, Déas, Olivier, Cairo, Stefano, Judde, Jean-Gabriel, Tagliabue, Elda, Iorio, Marilena V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021348/ https://www.ncbi.nlm.nih.gov/pubmed/29963251 http://dx.doi.org/10.18632/oncotarget.24723

Ejemplares similares

miR-205 in Breast Cancer: State of the Art
por: Plantamura, Ilaria, et al.
Publicado: (2020)

Breast Cancer Drug Resistance: Overcoming the Challenge by Capitalizing on MicroRNA and Tumor Microenvironment Interplay
por: Cosentino, Giulia, et al.
Publicado: (2021)

MiR-302b as a Combinatorial Therapeutic Approach to Improve Cisplatin Chemotherapy Efficacy in Human Triple-Negative Breast Cancer
por: Cataldo, Alessandra, et al.
Publicado: (2020)

The Role of MicroRNAs in HER2-Positive Breast Cancer: Where We Are and Future Prospective
por: Fogazzi, Valentina, et al.
Publicado: (2022)

MicroRNA and Oxidative Stress Interplay in the Context of Breast Cancer Pathogenesis
por: Cosentino, Giulia, et al.
Publicado: (2019)

The PDGFRβ/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer
por: Forte, Luca, et al.
Publicado: (2018)

miR-9-Mediated Inhibition of EFEMP1 Contributes to the Acquisition of Pro-Tumoral Properties in Normal Fibroblasts
por: Cosentino, Giulia, et al.
Publicado: (2020)

MicroRNAs and Triple Negative Breast Cancer
por: D’Ippolito, Elvira, et al.
Publicado: (2013)

Worldwide SARS-CoV-2 haplotype distribution in early pandemic
por: Cairo, Andrea, et al.
Publicado: (2022)

Aerosol 1,25-dihydroxyvitamin D3 supplementation: A strategy to boost anti-tumor innate immune activity
por: Bianchi, Francesca, et al.
Publicado: (2021)

MicroRNAs and DNA-Damaging Drugs in Breast Cancer: Strength in Numbers
por: Plantamura, Ilaria, et al.
Publicado: (2018)

CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers
por: Turdo, Federica, et al.
Publicado: (2016)

miR-302b enhances breast cancer cell sensitivity to cisplatin by regulating E2F1 and the cellular DNA damage response
por: Cataldo, Alessandra, et al.
Publicado: (2015)

Exosome-mediated delivery of miR-9 induces cancer-associated fibroblast-like properties in human breast fibroblasts
por: Baroni, S, et al.
Publicado: (2016)

Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study
por: Campiglio, M., et al.
Publicado: (2013)

Increased Sensitivity to Chemotherapy Induced by CpG-ODN Treatment Is Mediated by microRNA Modulation
por: De Cecco, Loris, et al.
Publicado: (2013)

Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit
por: Triulzi, Tiziana, et al.
Publicado: (2018)

Tumor Extracellular Matrix Remodeling: New Perspectives as a Circulating Tool in the Diagnosis and Prognosis of Solid Tumors
por: Giussani, Marta, et al.
Publicado: (2019)

What if the future of HER2‐positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study
por: Pizzamiglio, Sara, et al.
Publicado: (2021)

Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration
por: Triulzi, Tiziana, et al.
Publicado: (2015)

Correction: Intracellular STING inactivation sensitizes breast cancer cells to genotoxic agents
por: Gaston, Julie, et al.
Publicado: (2019)

Intracellular STING inactivation sensitizes breast cancer cells to genotoxic agents
por: Gaston, Julie, et al.
Publicado: (2016)

The lung microbiota: role in maintaining pulmonary immune homeostasis and its implications in cancer development and therapy
por: Sommariva, Michele, et al.
Publicado: (2020)

HER2 mRNA Levels, Estrogen Receptor Activity and Susceptibility to Trastuzumab in Primary Breast Cancer
por: Triulzi, Tiziana, et al.
Publicado: (2022)

HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy
por: Triulzi, Tiziana, et al.
Publicado: (2018)

Intratumor lactate levels reflect HER2 addiction status in HER2‐positive breast cancer
por: Castagnoli, Lorenzo, et al.
Publicado: (2018)

Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment
por: Rybinska, Ilona, et al.
Publicado: (2020)

Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group
por: Mackey, J.R., et al.
Publicado: (2008)

Adjuvant trastuzumab: progress, controversies, and the steps ahead
por: Joy, A.A., et al.
Publicado: (2006)

Effectiveness of adjuvant trastuzumab in daily clinical practice
por: Matos, Erika, et al.
Publicado: (2014)

Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34(+) cells in a xenograft model
por: Rossini, Anna, et al.
Publicado: (2012)

Macrophages Impair TLR9 Agonist Antitumor Activity through Interacting with the Anti-PD-1 Antibody Fc Domain
por: Camelliti, Simone, et al.
Publicado: (2021)

Radiation Recall Reaction Induced by Adjuvant Trastuzumab (Herceptin)
por: Chung, Caroline, et al.
Publicado: (2009)

High efficacy of CpG-ODN, Cetuximab and Cisplatin combination for very advanced ovarian xenograft tumors
por: Sommariva, Michele, et al.
Publicado: (2013)

ELISA assay employing epitope-specific monoclonal antibodies to quantify circulating HER2 with potential application in monitoring cancer patients undergoing therapy with trastuzumab
por: Agnolon, Valentina, et al.
Publicado: (2020)

Neoplastic and Stromal Cells Contribute to an Extracellular Matrix Gene Expression Profile Defining a Breast Cancer Subtype Likely to Progress
por: Triulzi, Tiziana, et al.
Publicado: (2013)

Cardiovascular Risk After Adjuvant Trastuzumab in Early Breast Cancer: An Italian Population‐Based Cohort Study
por: Franchi, Matteo, et al.
Publicado: (2020)

I205
por: Ristori, L
Publicado: (1995)

Trastuzumab in the adjuvant setting: concurrent or sequential? It takes two to tango!
por: Verma, Sunil
Publicado: (2008)

Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK
por: Earl, H.M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mej6ci84ruh0fd95cfaetnjqbh